Actually I think ONCS has potential on the upside from where it is at the moment.
Not sure if you listened to the most recent presentation Dan gave but he seemed upset with current share price to what results they had released which pushed share price down.
Again ONCS is trying to treat patients who are deaths door who have failed every other treatment. I think in this patient population ONCS results are looking pretty interesting, although early in trial, again only time will tell.
News 
Market Data 
Discover 
AI
